Welcome to our dedicated page for Kenvue news (Ticker: KVUE), a resource for investors and traders seeking the latest updates and insights on Kenvue stock.
Kenvue Inc. (KVUE) reports developments as a pure-play consumer health company with a brand portfolio that includes Tylenol, Listerine, Johnson’s, Aveeno, Neutrogena and BAND-AID Brand. Its updates center on consumer health categories, operating and financial results, and board actions such as cash dividends on common stock.
Recurring news themes also include material agreements, capital-structure matters, governance changes, shareholder voting topics and consumer-health regulatory disclosures. The coverage reflects Kenvue’s role as a public company operating branded everyday-care products across personal care, oral care, pain management and related health categories.
Kimberly-Clark (NASDAQ: KMB) has appointed Suzana Blades as Senior Vice President and General Counsel, effective September 1, 2026. She will report to Chief Strategy, Business Development and Administrative Officer Jeff Melucci and join Kimberly-Clark's Executive Leadership Team.
Blades is also named to the leadership team that will take effect upon completion of Kimberly-Clark's pending acquisition of Kenvue (NYSE: KVUE). She previously served as Vice President & Deputy General Counsel overseeing global litigation, government relations, legal operations and the Natural Solutions business, and earlier held senior legal roles at ConocoPhillips, Hess and Arnold & Porter.
Kenvue (NYSE: KVUE) reported fiscal Q2 2026 results for the quarter ended June 28, 2026, with Net sales up 3.0%, driven by 1.6% Organic sales growth and a 1.4% foreign currency benefit. Diluted EPS rose 9% to $0.24, while Adjusted diluted EPS increased 7% to $0.31. Gross profit margin was 58.2% (Adjusted 60.2%), and Operating income margin was 17.7% (Adjusted 22.1%), both modestly lower year over year.
All three segments – Self Care, Skin Health and Beauty, and Essential Health – delivered Net sales growth between 2.2% and 5.1%. For the first six months, operating cash flow reached $1.2 billion, with Free cash flow of $1.0 billion. The company highlighted FDA approval of Tylenol with Naproxen, a new OTC fixed-dose combination granted three-year exclusivity. Kenvue also referenced its pending cash-and-stock acquisition by Kimberly-Clark, expected to close in Q4 2026 subject to remaining foreign regulatory approvals and customary conditions, and a 2026 Restructuring Initiative targeting about $250 million in pre-tax charges to optimize operations.
Kenvue (NYSE: KVUE) announced that its Board of Directors has declared a quarterly cash dividend of $0.21 per share on its common stock, a 1.2% increase from the prior quarterly dividend. The dividend will be paid on August 26, 2026 to shareholders of record as of August 12, 2026.
Kenvue (NYSE: KVUE) plans to release its second quarter 2026 financial results before the market opens on August 6, 2026. Due to its pending transaction with Kimberly-Clark, Kenvue will not hold a quarterly earnings conference call. The earnings press release will be available at investors.kenvue.com.
Kenvue (NYSE: KVUE) reported Q1 2026 results: net sales +4.5%, organic sales +0.7%, diluted EPS $0.25 (+47%), adjusted diluted EPS $0.32 (+33%). Gross margin expanded to 58.9% and adjusted gross margin to 60.8%. Operating margin widened to 19.6% and adjusted operating margin to 24.0%. Free cash flow rose to $0.4 billion. The company reaffirmed the expected close of its Kimberly-Clark transaction in H2 2026, subject to regulatory approvals, and disclosed a 2026 restructuring charge of about $250 million.
Kenvue (NYSE: KVUE) announced a quarterly cash dividend of $0.2075 per share. The dividend is payable on May 27, 2026 to shareholders of record at the close of business on May 13, 2026. Contact information for investor and media relations was provided.
Kenvue (NYSE: KVUE) will announce its first quarter 2026 financial results before market open on May 7, 2026. Due to a pending transaction with Kimberly-Clark, Kenvue will not host a quarterly conference call.
The press release will be posted on the company's investor website at investors.kenvue.com. Investor and media contact emails are provided for follow-up.
Kimberly-Clark (NASDAQ: KMB) announced the post-closing organizational structure and named key leaders that will take effect after completing its pending acquisition of Kenvue, targeted to close in the second half of 2026. The combined company will operate four segments with estimated annual sales: North America $18.0B, EMEA $5.0B, Asia Pacific Focus Markets $4.3B, and Enterprise Markets $4.3B.
Mike Hsu will remain Chairman and CEO; a senior leadership roster and integration management office were disclosed to drive Day 1 readiness and identify growth and efficiency priorities.
Kenvue (NYSE:KVUE) reported Q4 2025 net sales +3.2% and organic sales +1.2%, with Q4 diluted EPS $0.17 and adjusted diluted EPS $0.27. Full year 2025 net sales declined 2.1% with diluted EPS $0.76 and adjusted diluted EPS $1.08. The company expects the Kimberly-Clark acquisition to close in H2 2026, subject to approvals.
Free cash flow rose to $1.7 billion and total debt was $8.5 billion as of December 28, 2025.
Kenvue (NYSE: KVUE) will report fourth quarter and full year 2025 results after market close on February 17, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not host a quarterly conference call; the press release will be posted at the company investor website.
Investor and media contacts are provided for follow-up.